RecruitingPhase 3NCT03562169

The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

Studying Post-transplant lymphoproliferative disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Leeds
Principal Investigator
Head of Trial Management
Univeristy of Leeds, CTRU
Intervention
Ixazomib, thalidomide, & dexamethasone (ITD) re-induction(drug)
Enrollment
406 target
Eligibility
18 years · All sexes
Timeline
2017 – 2027

Study locations (30)

Collaborators

Cancer Research UK · Takeda

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03562169 on ClinicalTrials.gov

Other trials for Post-transplant lymphoproliferative disease

Additional recruiting or active studies for the same condition.

See all trials for Post-transplant lymphoproliferative disease →

← Back to all trials